BIOADAPTIVES, INC. Overview
Industry: Packaged Foods
Sector: Consumer Defensive
BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements. It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute for humans; Canine Regen and Equine Regen for dogs and horses, as well as base formulations, including Equine All-in-One to trainers, horse owners and boarding stables; and All-in-One products, which combine minerals, vitamins, amino acids, and other botanicals with the Regen compounds. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada. BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements. It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute fo Read MoreMavefund brings filings, fundamentals, valuation, price history and news for BIOADAPTIVES, INC. into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Latest company-filed earnings material is available for source review.
What changed
- Review the SEC source filing for the full reported results and management commentary.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
BioAdaptives Completes Commercial Supply Chain Ahead of MyndSystem and Xcellara Launches
Headline from Yahoo Finance: BioAdaptives Completes Commercial Supply Chain Ahead of MyndSystem and Xcellara Launches.
BioAdaptives Inc. Announces Operational Readiness and
Headline from GlobeNewswire: BioAdaptives Inc. Announces Operational Readiness and.
BioAdaptives Outlines Xcellara Platform Strategy Ahead of XcellaraHeart Launch
Headline from Yahoo Finance: BioAdaptives Outlines Xcellara Platform Strategy Ahead of XcellaraHeart Launch.
BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness
Headline from Yahoo Finance Singapore: BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness.
BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness
Headline from GlobeNewswire: BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness.
BioAdaptives Announces XcellaraHeart Cardiovascular Wellness Formula Ahead of August Launch
Headline from Yahoo Finance: BioAdaptives Announces XcellaraHeart Cardiovascular Wellness Formula Ahead of August Launch.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.